RATIONALE AND OBJECTIVES: To evaluate the long-term clinical outcomes of magnetic resonance--guided high-intensity focused ultrasound (MR-g HIFU) treatments for symptomatic uterine leiomyomata. MATERIALS AND METHODS: Patients were recruited for a prospective study for MR-g HIFU treatments of symptomatic leiomyomata, with up to 3-year follow-up. The study was approved by the institutional review board and was Health Insurance Portability and Accountability Act--compliant. Clinical assessments were obtained at 3 months, 6 months, and 1, 2, and 3 years after MR-g HIFU, as well as uterine fibroid symptom severity scores (SSS) and health-related quality of life questionnaires (UFS-QOL). MR imaging was performed at each follow-up to assess the efficacy of the treatment at 6 months, 1 year, 2 years, and 3 years. RESULTS: Fifty-one leiomyomata in 40 patients were treated. All patients were treated within the US Food and Drug Administration guidelines with leiomyomata localized on MR and treated with sonication. The mean baseline volume of treated leiomyomata was 336.9 cm(3). The mean improvement scores for transformed SSS was 47.8 (P < .001) and for tUFS-QOL was 39.8 (P < .001) at 3 years. The mean volume decrease in treated leiomyomata was 32.0% (P < .001), and, in the uterus, the volume decrease was 27.7% (P < .001) at 3 years. There were no long-term complications. CONCLUSIONS: Long-term follow-up data from MR-g HIFU treatments show sustained symptomatic relief among enrolled patients. Although the results are preliminary, MR-g HIFU for the treatment of uterine leiomyomata may result in acceptable long-term outcomes at 3 years.
RATIONALE AND OBJECTIVES: To evaluate the long-term clinical outcomes of magnetic resonance--guided high-intensity focused ultrasound (MR-g HIFU) treatments for symptomatic uterine leiomyomata. MATERIALS AND METHODS:Patients were recruited for a prospective study for MR-g HIFU treatments of symptomatic leiomyomata, with up to 3-year follow-up. The study was approved by the institutional review board and was Health Insurance Portability and Accountability Act--compliant. Clinical assessments were obtained at 3 months, 6 months, and 1, 2, and 3 years after MR-g HIFU, as well as uterine fibroid symptom severity scores (SSS) and health-related quality of life questionnaires (UFS-QOL). MR imaging was performed at each follow-up to assess the efficacy of the treatment at 6 months, 1 year, 2 years, and 3 years. RESULTS: Fifty-one leiomyomata in 40 patients were treated. All patients were treated within the US Food and Drug Administration guidelines with leiomyomata localized on MR and treated with sonication. The mean baseline volume of treated leiomyomata was 336.9 cm(3). The mean improvement scores for transformed SSS was 47.8 (P < .001) and for tUFS-QOL was 39.8 (P < .001) at 3 years. The mean volume decrease in treated leiomyomata was 32.0% (P < .001), and, in the uterus, the volume decrease was 27.7% (P < .001) at 3 years. There were no long-term complications. CONCLUSIONS: Long-term follow-up data from MR-g HIFU treatments show sustained symptomatic relief among enrolled patients. Although the results are preliminary, MR-g HIFU for the treatment of uterine leiomyomata may result in acceptable long-term outcomes at 3 years.
Authors: Hyun S Kim; Jason Tsai; Ajanta Patra; Judy M Lee; John G Griffith; Edward E Wallach Journal: J Vasc Interv Radiol Date: 2006-05 Impact factor: 3.464
Authors: Gaylene Pron; Eva Mocarski; John Bennett; George Vilos; Andrew Common; Mukarram Zaidi; Kenneth Sniderman; Murray Asch; Roman Kozak; Martin Simons; Cuong Tran; John Kachura Journal: J Vasc Interv Radiol Date: 2003-10 Impact factor: 3.464
Authors: Scott C Goodwin; James B Spies; Robert Worthington-Kirsch; Eric Peterson; Gaylene Pron; Shuang Li; Evan R Myers Journal: Obstet Gynecol Date: 2008-01 Impact factor: 7.661
Authors: Bryan D Cowan; Patrick E Sewell; Jeffery C Howard; Richard M Arriola; Lynda G Robinette Journal: Am J Obstet Gynecol Date: 2002-06 Impact factor: 8.661
Authors: Carlo Masciocchi; Francesco Arrigoni; Fabiana Ferrari; Aldo Victor Giordano; Sonia Iafrate; Ilaria Capretti; Ester Cannizzaro; Alfonso Reginelli; Anna Maria Ierardi; Chiara Floridi; Alessio Salvatore Angileri; Luca Brunese; Antonio Barile Journal: Med Oncol Date: 2017-02-24 Impact factor: 3.064
Authors: Chung Y Kong; Lesley Meng; Zehra B Omer; J Shannon Swan; Serene Srouji; G Scott Gazelle; Fiona M Fennessy Journal: AJR Am J Roentgenol Date: 2014-08 Impact factor: 3.959